We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+7.79%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$51.8B
AUM Growth
+$2.19B
Cap. Flow
-$1.04B
Cap. Flow %
-2.01%
Top 10 Hldgs %
17.67%
Holding
2,975
New
68
Increased
781
Reduced
1,984
Closed
53

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$102M
2
XL
XL Group Ltd.
XL
+$28.4M
3
MSFT icon
Microsoft
MSFT
+$26.9M
4
CSCO icon
Cisco
CSCO
+$24.2M
5
GGP
GGP Inc.
GGP
+$24M

Sector Composition

Rank Sector Weight
1 Technology 18.16%
2 Financials 15.87%
3 Healthcare 13.94%
4 Consumer Discretionary 10.36%
5 Industrials 10.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BRSS
2126
DELISTED
Global Brass & Copper Hldgs, Inc
BRSS
$737K ﹤0.01%
19,981
-1,389
-6% -$48.6K
CAC icon
2127
Camden National
CAC
$983M
$735K ﹤0.01%
16,910
TPC
2128
Tutor Perini Cor
TPC
$4.99B
$733K ﹤0.01%
38,999
-50
-0.1% -$969
TALO icon
2129
Talos Energy
TALO
$2.34B
$732K ﹤0.01%
22,304
+1,480
+7% +$49.9K
RVNC
2130
DELISTED
Revance Therapeutics, Inc.
RVNC
$729K ﹤0.01%
29,328
-2,125
-7% -$57.8K
TELL
2131
DELISTED
Tellurian Inc.
TELL
$728K ﹤0.01%
81,131
-3,613
-4% -$29.8K
UTL icon
2132
Unitil
UTL
$971M
$727K ﹤0.01%
14,278
KPTI icon
2133
Karyopharm Therapeutics
KPTI
$44.6M
$726K ﹤0.01%
2,844
-178
-6% -$49.2K
CHRS icon
2134
Coherus Oncology
CHRS
$207M
$721K ﹤0.01%
43,718
-1,363
-3% -$24.2K
HBNC icon
2135
Horizon Bancorp
HBNC
$1.04B
$721K ﹤0.01%
36,531
+447
+1% +$9.18K
BCRX icon
2136
BioCryst Pharmaceuticals
BCRX
$2.42B
$718K ﹤0.01%
94,085
-895
-0.9% -$6.01K
DAKT icon
2137
Daktronics
DAKT
$1.05B
$718K ﹤0.01%
91,577
-1,008
-1% -$8.28K
FATE icon
2138
Fate Therapeutics
FATE
$296M
$718K ﹤0.01%
44,064
-3,050
-6% -$36.1K
NOG icon
2139
Northern Oil and Gas
NOG
$2.27B
$716K ﹤0.01%
17,900
+6,769
+61% +$229K
CYH icon
2140
Community Health Systems
CYH
$417M
$710K ﹤0.01%
205,305
+1,725
+0.8% +$5.61K
CASS icon
2141
Cass Information Systems
CASS
$747M
$709K ﹤0.01%
13,056
-948
-7% -$55K
DVAX
2142
DELISTED
Dynavax Technologies
DVAX
$708K ﹤0.01%
57,130
-3,575
-6% -$48.4K
PRTY
2143
DELISTED
Party City Holdco Inc.
PRTY
$708K ﹤0.01%
52,275
+18,209
+53% +$279K
ARII
2144
DELISTED
American Railcar Industries, Inc.
ARII
$708K ﹤0.01%
15,362
+67
+0.4% +$3.02K
XCRA
2145
DELISTED
Xcerra Corporation
XCRA
$704K ﹤0.01%
49,329
-3,040
-6% -$43.1K
THFF icon
2146
First Financial Corp
THFF
$963M
$703K ﹤0.01%
13,999
-29
-0.2% -$1.45K
IWP icon
2147
iShares Russell Mid-Cap Growth ETF
IWP
$20.7B
$700K ﹤0.01%
10,328
-22,396
-68% -$1.49M
CTMX icon
2148
CytomX Therapeutics
CTMX
$758M
$698K ﹤0.01%
37,741
+689
+2% +$15.7K
NVAX icon
2149
Novavax
NVAX
$1.26B
$698K ﹤0.01%
18,573
-219
-1% -$6.17K
GSBC icon
2150
Great Southern Bancorp
GSBC
$877M
$695K ﹤0.01%
12,553
+50
+0.4% +$2.94K

Similar funds

RhumbLine Advisers's Q3 2018 Portfolio in Review

As of Q3 2018, RhumbLine Advisers held 2,975 positions worth $51.8B, up 4.4% from $49.6B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Trading was light in Q3 2018: portfolio turnover was 4.1%. RhumbLine Advisers opened 68 new positions and exited 53, leaving the 2,975-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q3 2018 buy was iShares TIPS Bond ETF: 312,303 shares worth $34.5M.
  • RhumbLine Advisers added most to Williams Companies in Q3 2018, an estimated $16.4M increase.
  • RhumbLine Advisers's biggest Q3 2018 reduction was Apple, cutting an estimated $102M.
  • RhumbLine Advisers fully exited XL Group Ltd. in Q3 2018, selling an estimated $28.4M.
  • RhumbLine Advisers's ten largest holdings make up 18% of its $51.8B portfolio in Q3 2018.
  • RhumbLine Advisers opened 68 new positions and closed 53 in Q3 2018.
  • RhumbLine Advisers's portfolio value rose 4.4% quarter-over-quarter to $51.8B.

Based on RhumbLine Advisers's 13F filing for Q3 2018, filed 7 Nov 2018.